Loading ETF profile…
The State Street SPDR S&P Biotech ETF (XBI) is designed to closely track the total return performance of the S&P Biotechnology Select Industry Index, prior to accounting for fees and expenses. Its primary objective is to offer investors targeted exposure exclusively to the biotechnology segment of the market. A distinguishing characteristic is its underlying modified equal-weighted index, which fosters a diversified portfolio by ensuring balanced representation across large, mid, and small-capitalization biotech companies, thereby minimizing concentration risk. This structure makes XBI a precise tool for investors seeking to implement strategic or tactical allocations within the biotech sector, providing a more focused investment approach compared to traditional, broader sector funds.
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| APGE | APOGEE THERAPEUTICS INC | 1.49% | $156.32M |
| MRNA | MODERNA INC | 1.40% | $147.77M |
| PRAX | PRAXIS PRECISION MEDICINES I | 1.35% | $142.05M |
| TWST | TWIST BIOSCIENCE CORP | 1.35% | $141.51M |
| ORKA | ORUKA THERAPEUTICS INC | 1.34% | $140.85M |
| VKTX | VIKING THERAPEUTICS INC | 1.32% | $138.93M |
| KYMR | KYMERA THERAPEUTICS INC | 1.30% | $136.26M |
| ERAS | ERASCA INC | 1.27% | $133.39M |
| SLS | SELLAS LIFE SCIENCES GROUP I | 1.24% | $130.95M |
| CGON | CG ONCOLOGY INC | 1.24% | $130.90M |
| RVMD | REVOLUTION MEDICINES INC | 1.24% | $130.26M |
| MIRM | MIRUM PHARMACEUTICALS INC | 1.21% | $127.59M |
| CYTK | CYTOKINETICS INC | 1.21% | $126.86M |
| RYTM | RHYTHM PHARMACEUTICALS INC | 1.19% | $125.18M |
| PCVX | VAXCYTE INC | 1.18% | $123.91M |
| NTRA | NATERA INC | 1.17% | $122.66M |
| DNTH | DIANTHUS THERAPEUTICS INC | 1.16% | $122.09M |
| RLAY | RELAY THERAPEUTICS INC | 1.16% | $121.88M |
| TVTX | TRAVERE THERAPEUTICS INC | 1.16% | $121.62M |
| SRRK | SCHOLAR ROCK HOLDING CORP | 1.16% | $121.55M |
| COGT | COGENT BIOSCIENCES INC | 1.14% | $120.38M |
| ROIV | ROIVANT SCIENCES LTD | 1.13% | $119.20M |
| KRYS | KRYSTAL BIOTECH INC | 1.12% | $118.05M |
| SYRE | SPYRE THERAPEUTICS INC | 1.11% | $117.08M |
| ALKS | ALKERMES PLC | 1.11% | $116.84M |